Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 358 followers
Latest posts
Last updated 8 days ago
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
8 days ago
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
19 days ago
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
20 days ago
Giredestrant is the only oral SERD to show superior invasive disease-free survival...
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
21 days ago
The new PCR test aids in the diagnosis of infectious causes of...
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
21 days ago
Approval based on phase II NOBILITY and phase III REGENCY studies showing...
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
21 days ago
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed...
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
22 days ago
Overall survival was twice as long for people treated with Columvi in...
Reminder: Invitation to Roche’s Virtual Oncology/SABCS Investor Event
26 days ago
We are pleased to invite investors and analysts to participate in our...
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
28 days ago
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare...
Invitation to Roche’s Virtual Oncology/SABCS Investor Event
about 1 month ago
We are pleased to invite investors and analysts to participate in our...
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
about 1 month ago
Lunsumio provides high rates of deep and long-lasting responses in third-line and...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
about 1 month ago
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit...